UNCY
Unicycive Therapeutics, Inc.
Key Financials
Net Income
$-26555000
↑ 27.7%
Operating Income
$-29517000
↑ 8.1%
EPS (Diluted)
$-1.67
↓ 198.2%
Total Liabilities
$18.9M
↓ 21.9%
Total Assets
$49.1M
↑ 55.2%
Revenue
$675000
0.0%
Shareholders' Equity
$30.2M
↑ 306.4%
Cash & Equivalents
$29.2M
↑ 11.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/18/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| 10-Q | 5/12/2026 | View on SEC |
| S-8 | 5/6/2026 | View on SEC |
| ARS | 4/30/2026 | View on SEC |
| DEFA14A | 4/30/2026 | View on SEC |
| DEF 14A | 4/30/2026 | View on SEC |
| 8-K | 4/6/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | UNCY |
| Company Name | Unicycive Therapeutics, Inc. |
| CIK | 1766140 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-384-0642 |